Personalis (NASDAQ:PSNL) Lowered to "Sell" Rating by Wall Street Zen

Key Points

• Personalis' stock rating was downgraded from "hold" to "sell" by Wall Street Zen, reflecting concerns about the company's performance.
• Analysts have mixed opinions on Personalis, with one analyst issuing a sell rating while six analysts give it a buy rating, suggesting varied confidence in the stock's potential.
• Personalis reported earnings with a negative net margin of 113.70% and revenues falling short of estimates, indicating ongoing financial challenges for the company.

Personalis (NASDAQ:PSNL - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research report issued to clients and investors on Saturday.

A number of other research firms have also issued reports on PSNL. Guggenheim initiated coverage on Personalis in a report on Thursday, May 15th. They issued a "buy" rating and a $6.00 target price for the company. HC Wainwright cut their price objective on Personalis from $9.00 to $8.50 and set a "buy" rating for the company in a report on Wednesday, August 6th. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the company's stock. According to data from MarketBeat, Personalis currently has a consensus rating of "Moderate Buy" and an average price target of $7.42.

Personalis Stock Down 0.2%

NASDAQ PSNL traded down $0.01 on Friday, reaching $4.50. 958,774 shares of the stock traded hands, compared to its average volume of 1,073,203. The firm's fifty day simple moving average is $6.09 and its 200 day simple moving average is $4.90. The company has a market cap of $399.06 million, a price-to-earnings ratio of -3.52 and a beta of 1.86. Personalis has a 12 month low of $2.83 and a 12 month high of $7.79.

Personalis (NASDAQ:PSNL - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.25) by $0.02. The firm had revenue of $17.20 million during the quarter, compared to analyst estimates of $20.12 million. Personalis had a negative return on equity of 47.57% and a negative net margin of 113.70%. As a group, equities research analysts forecast that Personalis will post -1.4 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of PSNL. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Personalis in the fourth quarter valued at approximately $28,000. JPMorgan Chase & Co. raised its position in Personalis by 2,827.0% in the 4th quarter. JPMorgan Chase & Co. now owns 5,854 shares of the company's stock worth $34,000 after purchasing an additional 5,654 shares during the last quarter. Focus Partners Wealth bought a new position in Personalis in the 1st quarter worth approximately $47,000. Alpine Global Management LLC bought a new position in Personalis in the 4th quarter worth approximately $60,000. Finally, China Universal Asset Management Co. Ltd. raised its position in Personalis by 18.2% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 17,704 shares of the company's stock worth $62,000 after purchasing an additional 2,724 shares during the last quarter. Institutional investors own 61.91% of the company's stock.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.